XML 68 R39.htm IDEA: XBRL DOCUMENT

Segment, Geographical and Other Revenue Information (Tables)

12 Months Ended

Dec. 31, 2022

The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):


	Year Ended December 31, 2022						Year Ended December 31, 2021
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Revenues:
Product revenue	$	116,676	$	—	$	116,676	$	70,657	$	—	$	70,657
Research and development revenue	9,936		11,978		21,914		19,858		14,239		34,097
Total revenues	126,612		11,978		138,590		90,515		14,239		104,754
Costs and operating expenses:
Cost of product revenue	38,033		—		38,033		22,209		—		22,209
Research and development (1)	25,786		49,770		75,556		23,140		30,219		53,359
Selling, general and administrative(1)	14,724		2,421		17,145		12,105		2,755		14,860
Restructuring charges	1,708		966		2,674		—		—		—
Total segment costs and operating expenses	80,251		53,157		133,408		57,454		32,974		90,428
Income (loss) from operations	$	46,361	$	(41,179)	5,182		$	33,061	$	(18,735)	14,326
Corporate costs (2)					(33,080)						(32,201)
Depreciation and amortization					(5,418)						(3,215)
Loss before income taxes					$	(33,316)					$	(21,090)

(1) Research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases.

(2) Corporate costs include unallocated selling, general and administrative expense and restructuring charges, interest income, and other income (expense), net.


	Year Ended December 31, 2021						Year Ended December 31, 2020
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Revenues:
Product revenue	$	70,657	$	—	$	70,657	$	30,220	$	—	$	30,220
Research and development revenue	19,858		14,239		34,097		17,886		20,950		38,836
Total revenues	90,515		14,239		104,754		48,106		20,950		69,056
Costs and operating expenses:
Cost of product revenue	22,209		—		22,209		13,742		—		13,742
Research and development (1)	23,140		30,219		53,359		20,923		21,705		42,628
Selling, general and administrative (1)	12,105		2,755		14,860		9,597		2,355		11,952
Total segment costs and operating expenses	57,454		32,974		90,428		44,262		24,060		68,322
Income (loss) from operations	$	33,061	$	(18,735)	14,326		$	3,844	$	(3,110)	734
Corporate costs (2)					(32,201)						(22,306)
Depreciation and amortization					(3,215)						(2,099)
Loss before income taxes					$	(21,090)					$	(23,671)

(1) Research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases.

(2) Corporate costs include unallocated selling, general and administrative expense, interest income, and other income (expense), net.

The following table provides stock-based compensation expense included in income (loss) from operations (in thousands):


	Year Ended December 31,
	2022		2021		2020
Performance Enzymes	$	6,035	$	5,047	$	3,296
Novel Biotherapeutics	903		1,100		768
Corporate cost	7,593		5,446		3,664
Total	$	14,531	$	11,593	$	7,728

Schedule of Customers That Contributed 10% or More of Total Accounts Receivable

Customers that each accounted for 10% or more of our total revenues were as follows:


	Percentage of Total Revenues For the Year Ended December 31,
	2022		2021		2020
Customer A	56	%	33	%	*
Customer B	*		11	%	26	%
Customer C	*		*		19	%
Customer D	*		*		11	%
* Percentage was less than 10%

Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented are as follows:


	As of December 31,
	2022		2021
Customer A	53	%	62	%
Customer D	10	%	*
* Percentage was less than 10%

Schedule of Revenues by Geographical Area

Geographic revenues are identified by the location of the customer and consist of the following (in thousands):


	Year Ended December 31,
	2022		2021		2020
Revenues
Americas	$	17,000	$	23,481	$	24,352
EMEA	56,540		20,187		19,257
APAC	65,050		61,086		25,447
Total revenues	$	138,590	$	104,754	$	69,056

Schedule of Long-lived Assets by Geographical Area

Identifiable long-lived assets by location was as follows (in thousands):


	December 31,
	2022		2021
United States	$	61,877	$	65,457

Schedule of Intangible Assets and Goodwill

Identifiable goodwill by reporting unit was as follows (in thousands):


	December 31, 2022						December 31, 2021
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Goodwill	$	2,463	$	778	$	3,241	$	2,463	$	778	$	3,241